产品

数据

资源

预约演示

更新于：2025-05-07

ASTE1

更新于：2025-05-07

基本信息

别名

ASTE1、asteroid homolog 1、HT001

+ [1]

简介

Structure-specific DNA endonuclease that specifically cleaves single-stranded DNA and 3' overhang DNA. Contributes to the control of DNA double-strand break repair choice by antagonizing BRCA1-dependent homologous recombination (HR) and promoting non-homologous end-joining (NHEJ). Recruited to the single-stranded DNA ends by SHLD2 and cleaves the 3' exposed DNA ends, therefore inhibiting DNA end resection (necessary for HR) and promoting DNA end protection (necessary for NHEJ).

关联

项与 ASTE1 相关的药物

FMPV-3

靶点

ASTE1 x TAF1B x TGFBR2

作用机制

ASTE1调节剂 [+2]

在研机构

Hubro Therapeutics AS

原研机构

Hubro Therapeutics AS

在研适应症

遗传性非息肉病性结直肠癌

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

FMPV-2

靶点

ASTE1

作用机制

ASTE1调节剂 [+1]

在研机构

Hubro Therapeutics AS

原研机构

Hubro Therapeutics AS

在研适应症

子宫内膜癌

非在研适应症

结直肠癌

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 ASTE1 相关的临床结果

登录后查看更多信息

100 项与 ASTE1 相关的转化医学

登录后查看更多信息

0 项与 ASTE1 相关的专利（医药）

登录后查看更多信息

项与 ASTE1 相关的文献（医药）

2021-08-01·Nature Cell Biology

ASTE1 promotes shieldin-complex-mediated DNA repair by attenuating end resection

Article

作者: Zhou, Qin ; Liu, Yilun ; Guo, Guijie ; Hu, Qi ; Kim, Wootae ; Gao, Huanyao ; Gao, Ming ; Zhang, Yong ; Zhang, Chao ; Yuan, Jian ; Luo, Kuntian ; Tu, Xinyi ; Deng, Min ; Chen, Shih-Hsun ; Yin, Ping ; Liu, Chao ; Lou, Zhenkun ; Qin, Sisi ; Qin, Bo ; Kloeber, Jake A ; Zhao, Fei ; Nowsheen, Somaira ; Chen, Yuping ; Huang, Jinzhou

The shieldin complex functions as the downstream effector of 53BP1-RIF1 to promote DNA double-strand break end-joining by restricting end resection. The SHLD2 subunit binds to single-stranded DNA ends and blocks end resection through OB-fold domains. Besides blocking end resection, it is unclear how the shieldin complex processes SHLD2-bound single-stranded DNA and promotes non-homologous end-joining. Here, we identify a downstream effector of the shieldin complex, ASTE1, as a structure-specific DNA endonuclease that specifically cleaves single-stranded DNA and 3' overhang DNA. ASTE1 localizes to DNA damage sites in a shieldin-dependent manner. Loss of ASTE1 impairs non-homologous end-joining, leads to hyper-resection and causes defective immunoglobulin class switch recombination. ASTE1 deficiency also causes resistance to poly(ADP-ribose) polymerase inhibitors in BRCA1-deficient cells owing to restoration of homologous recombination. These findings suggest that ASTE1-mediated 3' single-stranded DNA end cleavage contributes to the control of DSB repair choice by 53BP1, RIF1 and shieldin.

2021-08-01·Nature Cell Biology

ASTE1 cutting to block DNA end resection

Article

作者: He, Yizhou Joseph ; Chowdhury, Dipanjan

Cells rely on two main pathways to repair DNA lesions, homologous recombination and non-homologous end-joining, and how they decide to use one machinery over the other is not clear.A recent study identifies ASTE1 as a regulator controlling pathway choice.

2020-09-01·Clinical Cancer Research

A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial

Article

作者: Al-Batran, Salah-Eddin ; Pauligk, Claudia ; Reuschenbach, Miriam ; Kloor, Matthias ; Rafiyan, Mohammad-Reza ; Karbach, Julia ; Jäger, Elke ; Tariverdian, Mirjam ; von Knebel Doeberitz, Magnus

AbstractPurpose:DNA mismatch repair (MMR) deficiency is a hallmark of Lynch syndrome, the most common inherited cancer syndrome. MMR-deficient cancer cells accumulate numerous insertion/deletion mutations at microsatellites. Mutations of coding microsatellites (cMS) lead to the generation of immunogenic frameshift peptide (FSP) neoantigens. As the evolution of MMR-deficient cancers is triggered by mutations inactivating defined cMS-containing tumor suppressor genes, distinct FSP neoantigens are shared by most MMR-deficient cancers. To evaluate safety and immunogenicity of an FSP-based vaccine, we performed a clinical phase I/IIa trial (Micoryx).Patients and Methods:The trial comprised three cycles of four subcutaneous vaccinations (FSP neoantigens derived from mutant AIM2, HT001, TAF1B genes) mixed with Montanide ISA-51 VG over 6 months. Inclusion criteria were history of MMR-deficient colorectal cancer (UICC stage III or IV) and completion of chemotherapy. Phase I evaluated safety and toxicity as primary endpoint (six patients), phase IIa addressed cellular and humoral immune responses (16 patients).Results:Vaccine-induced humoral and cellular immune responses were observed in all patients vaccinated per protocol. Three patients developed grade 2 local injection site reactions. No vaccination-induced severe adverse events occurred. One heavily pretreated patient with bulky metastases showed stable disease and stable CEA levels over 7 months.Conclusions:FSP neoantigen vaccination is systemically well tolerated and consistently induces humoral and cellular immune responses, thus representing a promising novel approach for treatment and even prevention of MMR-deficient cancer.